SCN3A

Sodium channel protein type 3 subunit alpha · Q9NY46 · SCN3A on Sugi Atlas →

90,417 patent compounds predicted against SCN3A, 57,026 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ambucaine (SCHEMBL82280)	0.91	8/20
SCHEMBL135105	0.56	8/20
SCHEMBL135106	0.56	8/20
Metabutoxycaine (SCHEMBL25778)	0.58	7/20
Propoxycaine (SCHEMBL83073)	1.00	6/20
Propoxycaine (SCHEMBL24720)	0.98	6/20
Biphenamine (SCHEMBL25980)	0.81	6/20
Chloroprocaine (SCHEMBL6676)	0.67	6/20
Benoxinate (SCHEMBL25087)	1.00	5/20
Betoxycaine (SCHEMBL25758)	0.77	5/20
Procaine (SCHEMBL3524)	0.68	5/20
Chloroprocaine (SCHEMBL24096)	0.66	5/20
Phthalylsulfacetamide (SCHEMBL49529)	0.59	5/20
Pramipexole (SCHEMBL35376)	0.56	5/20
Dexpramipexole (SCHEMBL74780)	0.56	5/20
Pramipexole (SCHEMBL42113)	0.55	5/20
SCHEMBL517	0.40	5/20
Proparacaine (SCHEMBL23334)	1.00	4/20
SCHEMBL25906	1.00	4/20
SCHEMBL25907	1.00	4/20

Clinical trials — most relevant to SCN3A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations	PHASE4	COMPLETED
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome	PHASE3	RECRUITING
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
Suzetrigine in Total Hip Arthroplasty	PHASE3	RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Prospective Study to Determine the Prevalence of Signs of Central Sensitization in Adults With ASD Without Intellectual Developmental Disorders	nan	RECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
Painful Channelopathies Study	nan	UNKNOWN
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients	nan	COMPLETED
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Probing the Role of Sodium Channels in Painful Neuropathies	nan	UNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SCN3A binder may also engage these)

Protein	Name	Similarity
SCN2A	Sodium channel protein type 2 subunit alpha	1.000	landscape →
P04775	—	1.000	P04775 →
P08104	—	1.000	P08104 →
B1AWN6	—	1.000	B1AWN6 →
A2ASI5	—	1.000	A2ASI5 →
O88420	—	1.000	O88420 →
Q62205	—	1.000	Q62205 →
Q28644	—	1.000	Q28644 →
SCN1A	Sodium channel protein type 1 subunit alpha	1.000	landscape →
Q9WTU3	—	1.000	Q9WTU3 →
Q2XVR7	—	1.000	Q2XVR7 →
Q62968	—	1.000	Q62968 →
SCN9A	Sodium channel protein type 9 subunit alpha	1.000	landscape →
P15390	—	1.000	P15390 →
Q2XVR3	—	1.000	Q2XVR3 →
A2APX8	—	1.000	A2APX8 →
SCN8A	Sodium channel protein type 8 subunit alpha	1.000	landscape →
P04774	—	1.000	P04774 →
Q6QIY3	—	1.000	Q6QIY3 →
P15389	—	0.999	P15389 →
Q9JJV9	—	0.999	Q9JJV9 →
O08562	—	0.998	O08562 →
P02719	—	0.998	P02719 →
Q20JQ7	—	0.998	Q20JQ7 →
Q9ER60	—	0.998	Q9ER60 →
Q2XVR6	—	0.998	Q2XVR6 →
P35500	—	0.997	P35500 →
Q28371	—	0.997	Q28371 →
SCN10A	Sodium channel protein type 10 subunit alpha	0.996	landscape →
SCN5A	Sodium channel protein type 5 subunit alpha	0.996	landscape →